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ABSTRACT 
Signalling lymphocyte activation molecule (SLAM) F7 is found on the surface of some immune 
cells including B-lymphocytes. Its activation leads to the proliferation or differentiation of im-
mune cells. The objectives of the study were to measure SLAMF7 expression levels on B-CLL 
cells, and to upregulate the expression of SLAMF7 with phorbol myristate acetate (PMA) and 
Bryostatin. The levels of expression of SLAMF7 receptors of B-CLL cells from patients were 
measured; using immunofluorescence, flow cytometry, confocal microscopy and reverse tran-
scriptase polymerase chain reaction (RT-PCR). The effects of treatments with PMA and Bry-
ostatin were determined from different patients. Different levels of SLAMF7 expression were 
found to be associated with B-CLL cells from different patients. PMA treatment of B-CLL cells 
showed more positive SLAMF7 staining with the majority of the extracted B-CLL cell cases, 
while less positive results were associated with Bryostatin treatment. The study has shown that 
both PMA and Bryostatin could upregulate SLAMF7. Successful modulation of SLAMF7 ex-
pression may provide a novel target for the treatment of patients with CLL. 
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INTRODUCTION 
Signalling lymphocyte activation molecule 
(SLAM) F7, is among the members of SLAM 
family of receptors found on the surface of 
some specific immune cells that regulate sev-
eral functions of different immune cell types 
(Murphy et al., 2002; Bouchon et al., 2001; 
Veillett and Latour, 2003; Lee et al., 2007; 
Stark and Watzl, 2006). According to the Hugo 
Gene Nomenclature (2012), SLAMF7 contains 
one immunoglobulin-like C2-type domain. Ex-
pression of SLAMF7 can be found in lymph 
nodes, bone marrow, stomach, trachea, spleen, 
lungs, appendix, small intestine and peripheral 
leucocytes (Calpe t al., 2008).  
 
Activation of SLAMF7 receptor leads to stimu-
lation of the signal transduction pathway, 
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which results in the proliferation or differentia-
tion of the immune cell (Cambier et al., 1994; 
Jiang et al., 2005). Currently, a monoclonal 
antibody, Elotuzumab used in the treatment of 
multiple myeloma is known to target SLAMF7 
(Richardson et. al., 2011) and has been success-
fully targeted with Elotuzumab, a novel drug 
for the treatment of CLL (Murphy et al., 2002). 
 
Protein kinase C (PKC) activators like phorbol 
esters and Bryostatins affect the signal trans-
duction pathway, which has enormous effect on 
a variety of biological responses, which include 
proliferation and differentiation (Cambier and 
Ransom, 1987; King, 1988; Isakov et al., 1986; 
Muhie et al., 2013). Bryostatins are antipromot-
ers of tumour cells (Hennings et al., 1990); 
hence they are more significant in clinical tri-
als, than phorbol esters like phorbol myristate 
acetate (PMA), which are carcinogenic 
(Nishimoto et al., 2013; Hennings et al., 1987). 
The optimal concentration for Bryostatin 
modulation of SLAMF7 is suggested to be 
10nM (Drexler et al., 1989), which has been 
corroborated by Murphy et al. (2002). This 
study aims to upregulate the expression of 
SLAMF7 receptors with protein kinase C 
(PKC) activators (Bryostatin and PMA). Suc-
cessful modulation of SLAMF7 expression 
may provide a novel target for the treatment of 
patients with chronic lymphocytic leukaemia. 
 
MATERIALS AND METHODS 
Sample population  
Between July 2013 and August 2013, consecu-
tive samples of CLL patients were selected for 
the study. Blood samples were collected from 
the CLL patients attending the oncology clinic 
(Department of Haematology, UCL Cancer 
Research Institute) at the University College of 
London Hospital, London, UK. They were ana-
lysed at the University of Westminster Immu-
nology Laboratory. The samples collected were 
from twenty-two patients with the malignancy 
who were from different ethnic backgrounds. 
Twelve (12) of them who had significant 
amount of white cell counts (5x105 cells/ml) 
were subsequently enrolled into the study. 
Stored frozen multiple myeloma cells and some 
B-CLL cells were obtained from University of 




Whole blood samples collected by venepunc-
ture were processed immediately by extracting 
the white blood cells (WBC). 8 mls of blood 
sample was added to equal volume of RPMI 
1640 medium with L-glutamine (Sigma-
Aldrich Company Ltd, UK) and mixed. 15mls 
of histopaque reagent (Sigma-Aldrich Com-
pany Ltd, UK) was added to 10mls of the 
blood: RPMI mixture previously constituted. 
The addition was done carefully drop by drop 
unto the surface of the histopaque, taking care 
that it settled on the top of the histopaque. The 
new mixture was centrifuged at 2500 rpm at 
22oC for 30 minutes. This was to allow all other 
cells to go through the semi-solidified histo-
paque, while leaving the white cells on top. 
Approximately 3mls of B-CLL cells suspended 
on the surface of the histopaque was carefully 
transferred into a universal tube, and RPMI 
1640 medium was added. Further centrifuga-
tion at 1500 rpm at 4oC and for 5 minutes was 
done to obtain a pure sample with minimal con-
tamination from other cells. The supernatant 
was decanted and white cell pellets (B-CLL 
cells) were resuspended in the remaining me-
dium and counted in the Neubauer chamber. 
Subsequently RNeasy Minikit (Qiagen, UK) 
was used to isolate 1µg of its ribonucleic acid 
(RNA) following the manufacturer’s protocol. 
 
Samples that could not be processed immedi-
ately were stored in liquid nitrogen. A mini-
mum of 5 x 105 cells/ml was required for selec-
tion and running in each experiment. 
 
Cell culture testing  
A concentration of 0.5x106 B-CLL cells was 
cultured using RPMI-1640 as medium in a six-
well culture plate (Thermo Fisher Scientific, 
Sigma-Aldrich).  Duplicates of test (wells with 
PMA or Bryostatin treatment) and control 
(wells without PMA or Bryostatin treatment)  
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were prepared following standard protocol, as 
described by Murphy et al. (2002). Cells of test 
samples were stimulated with a 30 nM concen-
tration of PMA (Sigma, Poole, Dorset), or a 10 
nM Bryostatin (Sigma, Poole, Dorset). Addi-
tionally, a dose-response testing, using 0 nM, 
10 nM, 20nM and 40 nM of Bryostatin was 
done, followed by 24 hours incubation at 370 C 
with antibiotics (L-glutamine and penicillin/
streptomycin) and 10% v/v foetal bovine serum 
(Sigma-Aldrich, UK). The result showed suc-
cessful proliferation and differentiation of the B
-CLL cells after treatment with Bryostatin. The 
dose-response study also showed that the opti-
mal dose for proliferation and differentiation of 
the B-CLL cells using Bryostatin was 10 nM. 
 
Immunofluorescence testing 
Cells obtained from the culture study were re-
suspended, washed twice with phosphate buffer 
saline and 0.1% bovine serum antibody, 
(staining solution mixture) and transferred into 
a 5ml falcon tube following the protocol by 
Murphy et al. (2002). 5 µl of Anti-SLAMF7 
purified mouse monoclonal IgG2a (R&D sys-
tems, Minneapolis, MN) was added to the sus-
pended pellets. The Anti-SLAMF7 purified 
mouse monoclonal IgG2a then binds with 
SLAMF7 receptors (antigen) forming antigen-
antibody complex on the B-CLL cells, if pre-
sent, and served as positive control, while Ig-
GA2 which does not contain Anti-SLAMF7 
antibody was added in a second falcon tube as 
negative control, before incubating at 4oC on 
ice. After washing with the staining solution 
mixture the cells were stained with Fluorescein 
Isothiocyanate (FITC) labelled polyclonal goat 
anti mouse IgG (Dako Company, Denmark).  
 
Flow cytometry assay 
The cells obtained from the immunofluores-
cence testing were subjected to flow cytometry 
testing to determine the level of SLAMF7 re-
ceptors on the B-CLL cells following standard 
protocol provided by Dako Company. The re-
sults were recorded as mean fluorescence inten-
sity (MFI) and percentage positive of SLAMF7 
receptors on the cell surface. Control samples  
(without Anti-SLAMF7 treatment) showed low 
expression levels while positive test samples 
(with Anti-SLAMF7 IgG2a) showed positive 
results. Flow cytometry was also used to deter-
mine the optimal dose response using Bry-
ostatin treatment. 
 
Confocal microscopy  
The levels of expression/fluorescence of the 
SLAMF7 receptors were determined on the B-
CLL cell prior to the treatment and after treat-
ment of the cells. This was visualised using a 
confocal microscope to detect the dye fluores-
cence on the cell surfaces. The observation was 
done in the dark room (to avoid sunlight inter-
acting with the dye) using the Leica TCS SP2 
confocal microscopy system (Leica Microsys-
tems, Milton Kynes, and UK).   
 
Reverse transcriptase polymerase chain re-
action (RT-PCR)  
This was performed to identify the presence 
and level of expressing mRNA of SLAMF7 
receptors on B-CLL cells before and after 
upregulation. This involved RNA extraction 
using RNeasy Minikit (Qiagen Sample and 
Assay Technologies, UK), in accordance with 
the manufacturer’s protocol. The pure sample 
of the white cells was harvested by adding 
buffer RLT (350 µL) from the Qiagen kit. Sam-
ples were then passed through several washes 
with Qiagen reagent buffers, which were placed 
in a RNeasy spin column and were centrifuged 
at ≥ 8000 x g for 15s. The resulting total RNA 
was extracted into approximately 50 µL of 
RNase free water and measured spectropho-
tometrically using the Nanodrop automated 
machine (Thermo Scientific, USA) (at an ab-
sorbance of 260nm and 280nm) to determine 
the right molecular weight for RT-PCR. The 
optimal RNA ratio read by the Nanodrop Spec-
trophometer for the samples was 1:1.9 - 2.1. 
This indicates the purity of the sample being 
analysed, because a lower ratio than 1.9 suggest 
the presence of contaminants, such as proteins 
that absorb UV light. An amount of RNA (1µg) 
was measured and was reverse-transcribed to 
produce cDNA. Random primers and oligo-dT,  
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Bryostatin using cell culture and flow cy-
tometry studies  
Initial studies undertaken to establish the opti-
mal concentration of Bryostatin for upregula-
tion of SLAMF7 showed that Bryostatin treat-
ment was effective at an optimal concentration 
of 10 nM. (Table 1). 
 
The effect of Bryostatin on the receptors of 
SLAMF7 modulation on B-CLL cells showed 
that 10 nM produced the highest peak of 
SLAMF7 expression, but the expression de-
clined after the concentrations were subse-
quently increased to 20 nM and 40 nM. This 
trend was observed with all cases of B-CLL 
patients selected for dose-response testing. 
 
Cell culture and morphological features of B
-CLL cells 
It was observed that culture plates treated with 
PMA had the most cells aggregating or forming 
clusters that led to clumps in certain areas on 
the plates (Fig 1). Untreated medium had fairly 
evenly distributed cells on the plate with little 
evidence of clumping (Fig 1A). 
 
Bryostatin treatment also showed some clump 
formation (Fig 1C), even though they were in 
fewer areas, compared to clumping occurring  
using the GO TAG SYBR green PCR kit 
(Promega Corporation, UK) with Biometra 
PCR machine (Thistle Scientific, UK). The 
forward primer 5’-GCCAAT GAGTCC 
CATAAT-3’ and the reverse primer 5’-
GTATTT GCTGGA TCTTCC-3’ (Life Tech-
nologies Invitrogen Corporation, UK) were 
used to amplify the cDNA material. A 2% aga-
rose gel electrophoresis was run, using TRIS/
Borate/EDTA (TBE) at 100 volts for 40 min-
utes. The molecular weight marker of 100bp 
was used (Promega Corporation, Madison, 
USA) as a control ladder for the amplified 
cDNA product. Ethidium bromide was used in 
staining the DNA to enable the products to be 
visualised using an ultra violet (UV) Trans Illu-
minator Imaging System (UVItec Limited, 
Cambridge, UK).  
 
Ethical Approval  
Ethical clearance was obtained from two bod-
ies; the Committee on Human Research Publi-
cation and Ethics, School of Life Sciences, 
University of Westminster and Department of 




Establishing the optimal dose response of  
These were results obtained when the optimal concentration of bryostatin was determined. The B-CLL cells were from three 
patients; JL, JH and FW. The cells were used in the flow cytometer study, in which the cells under the influence of some 
stimulators, expressed SLAMF7 receptors, the presence of which was detected by fluorescence. FW could show a high level 
of expression even in the untreated state. This confirms the high level of expression of these receptors in untreated B-CLL 
cells. It also confirms the optimal concentration of Bryostatin at 10 nM. The B-CLL cells were from 3 patients, JL, JH and 
FW. 
   JL JH FW 
Conc.  %Pos MFI %Pos MFI %Pos MFI 
0 nM     0.94 5.52 6.94 3.56 13.37 4.47 
10 nM 1.32* 5.54* 16.11* 5.31* 12.42* 4.04* 
20 nM 0.78 5.19 15.91 5.29 11.81 3.62 
40 nM 0.61 5.09 4.02 2.82 3.2 1.87 
Table 1: Bryostatin dose response values using flow cytometry  
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with PMA. It thus suggests that PMA treatment 
caused the most increase in induction of the 
SLAMF7 receptor and cell clumping (Fig. 1B). 
 
The levels of expression of SLAMF7 recep-
tors on B-CLL cells of patients 
To determine the level of SLAMF7 receptors 
on B-CLL cells, the cells were exposed to var-
ied conditions: untreated, PMA and with Bry-
ostatin. The levels of expression of positive 
SLAMF7 were studied and the results indicated 
that different B-CLL cells expressed different 
levels. Two (2) out of the twelve (12) cases 
(17%) studied showed more than 40% positiv-
ity for SLAMF7 cells when untreated (Fig 2). 
More than 40% (5 out of the 12 cases) of B-
CLL cells studied were positive (above 10% 
positivity) for SLAMF7, 83% (10 out of the 12) 
of these cases also showed expression level 
below 10% positivity.  
 
Approximately 50% of all cases studied had 
two fold increases in the percentage positivity 
of SLAMF7 expression when the untreated 
cells were subsequently treated with PMA.  
However, cells from the 2 B-CLL cases, which  
had a high percentage positivity of SLAMF7 
xpression, did not show much increase when 
treated with PMA. One (1) case, representing 
8% of the cases studied, showed a decrease in 
the level of expression after treatment with 
PMA. However, there was slight increase of 
SLAMF7 expression when the same case was 
subjected to Bryostatin treatment.  
 
Similarly, 3 out of the 12 (25%) studied 
showed a decrease in modulation with Bry-
ostatin while 9 out of 12 (75%) had elevated 
positive cells after modulation with Bryostatin.  
Whilst 75% (9/12) of cases showed greater 
increase in the level of SLAMF7 modulation 
with PMA than with Bryostatin, 17% (2/12) 
showed higher SLAMF7 expression levels with 
Bryostatin than with PMA with only 1/12 
showing equal increase in SLAMF7 modula-
tion with both PMA and Bryostatin drugs.  
 
Expression of SLAMF7 receptors using con-
focal microscopy 
To confirm and establish the results showing 
high level of expression associated with B-CLL 
as seen in our study, we further studied the  
Fig. 1: Morphological changes of B-CLL cells after cell culturing when untreated and treated 
with PMA and bryostatin   
Photomicrographs were taken with Wilovert inverted microscope fitted with Olympus camera after 24 hours of incubation. 
Photomicrograph A shows cells without treatment used as a negative control where cells do not adhere to each other or 
form clumps. Photomicrograph B shows high number of cells clustered together in clumps after treatment with PMA. Pho-
tomicrograph C show moderate to high number of cells clustered together with some mild forms of clump formations after 
treatment with Bryostatin  
Large Cells 
Cell Clumps 
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level of fluorescence on selected positive and 
negative cases recorded from the flow cytome-
try results. Results obtained confirmed the high 
level of SLAMF7 expression on some untreated 
B-CLL cells. Recorded results from the light 
microscopy (Fig 3A) and from the confocal 
microscope (Fig 3B and 3C) of case JH showed 
fluorescence on the surface of the immunofluo-
rescence stained SLAMF7 cells (Fig. 3B) 
whereas the control staining (irrelevant anti-
body) was negative (Fig. 3C). However, there 
were no green patches of fluorescence seen on 
the negative case BD. This also gave a negative 
resul t  from f low Cytometry.  (Fig.3E). 
 
Expression of SLAMF7 isoforms as meas-
ured by RT-PCR 
To confirm the expression of two SLAMF7 
isoforms in B-CLL cells, we conducted studies 
using RT-PCR amplification. Selected B-CLL 
cells without treatment were used and extracted 
RNA converted to cDNA. Using selected mye-
l o m a  c e l l s  a s  c o n t r o l s ,  a m p l i f i e d   
cDNA product from the control, showed one 
strong band (396 bp) and a weak band (296 bp) 
(Fig 4), representing two isoforms associated 
with myeloma cells (OMLS and MMLS). The 
test results of B-CLL cells showed two less 
intense bands, confirming the presence of low 
levels of SLAMF7 isoforms in B-CLL cells.  
 
DISCUSSION 
The study observed that the optimal dose for 
upregulating B-CLL cells was 10 nM (table 1). 
This is in agreement with previous observation 
by Drexler et al. (1989) who reported the same 
concentration for Bryostatin for effective 
upregulation of SLAMF7 on B- CLL cells. 
Other studies have established similar concen-
tration for phorbol esters in inducing increase 
in SLAMF7 receptors on the cell surface 
(Murphy et al., 2002). 
 
B-CLL cells responded to treatment with PMA 
and Bryostatin by cellular proliferation and 
aggregation. This was evident as abnormal  
 
Fig. 2: SLAMF7 expressions in response to exposure to different conditions 
B-CLL cells from different patients were exposed to different conditions (untreated, PMA, bryostatin), for the expression of 
SLAMF7 receptors, which were measured by fluorescence in the flow cytometer. Each peak in the graph, showing percent-
age SLAMF7 positivity, represents a response generated from the Dako flow cytometer. FW, CB, BD, LP, MD, DS, PC, PII, 
SJ, JH, JL and JK are codes of B-CLL patients whose white cells were used. 
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 Green patches 
of fluorescence 
on B-CLL cell 
surface 
Fig. 3: Confocal microscopy showing positive and negative immunofluorescence for selected 
SLAMF7 B-CLL cell.  
Two patients samples measured for high and low expression levels of SLAMF7 with flow cytometry were selected for obser-
vation of immunofluorescence under the confocal microscope. Pictures A, B and C represent positive SLAMF7 B-CLL cell 
with FIT C-labelled dye. These fluoresced with green colour under a confocal microscope as observed in B and C pictures 
and as a white patch on a black and white background as seen with picture A. Pictures E and F were negative for SLAMF7 
expression on the selected B-CLL cell with FIT C-labelled dye.  
 
Fig. 4: Ethidium bromide-stained gels showing isoforms of SLAMF7 expression 
Two multiple myeloma cell lines are shown which had positive expression of SLAMF7. The cDNA of SLAMF7 was run on 
agarose gel electrophoresis, using a 100kb molecular marker. Lanes 2 and 4 produced a strong and a weak band. OMLS 
and MM1S were the myeloma cells used as positive control; both show the two bands representing the isoforms of SLAMF7. 
The cell from patient CB also showed two bands of equal intensity 
Band 1 (SLAMF7 AI) 
Band 2 (SLAMF7A2) 
 
Band 3 (UNSPECIFIC) 
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morphological characteristics, seen as clumps 
and clusters of enlarged B-CLL cells (Fig. 1). 
Some B-CLL cells however, did not show any 
any abnormal morphological characteristics. 
However, the lack of response of some of the 
other cells cannot be explained. The character-
istic feature of clumped and enlarged cell is 
similar to observation by Springer t al., (1987) 
and Springer (1990) who indicated that activa-
tion of lymphocytes is coupled with the in-
creased formation of clumps. It was evident 
however, that PMA induced more cellular pro-
liferation and aggregation, hence more clump-
ing to each other B-CLL cells than Bryostatin 
(Figs. 1B and 1C). 
 
SLAMF7 receptors have been found to play an 
important role in the activation of B-CLL cells, 
thus resulting in proliferation and/or differen-
tiation of these cells (Cambier et al., 1994; Ji-
ang et al., 2005). In our study, SLAMF7 recep-
tors showed varying levels of expression on B-
CLL cells using immunofluorescence, flow 
cytometry and confocal microscopy, which is 
in agreement with observations by Williams et 
al. (2004) and Williams et al. (2013). This re-
sult is however, contrary to what had been pre-
viously suggested, that all B-CLL cells express 
low levels (below 10% positivity) of SLAMF7 
or show complete absence of SLAMF7 expres-
sion (Hsi et al., 2008).  
 
When B-CLL cells were treated with PMA in
vitro, the cells were shown to portray varied 
characteristics, from the change in shape, size, 
extensions and cell numbers when stimulated 
by PKC activators (Drexler et al., 1989) in the 
signal transduction pathway. Our study showed 
83 % (10 out of the 12 cases) responding posi-
tively to PMA treatment, compared with 75% 
(9 out of the 12 cases) of B-CLL cases that 
responded to Bryostatin treatment (Fig 2). This 
is in conformity with observation by Drexler t 
al. (1989), and Garcia et al.(2006). More than 
50% of cases however showed different levels 
of positivity for SLAMF7 expression before 
treatment with PMA or Bryostatin.  
 
This study as shown in Fig 4, found two iso-
forms of SLAM receptors, namely SLAMF7 
and SLAMF7A2, on the B-CLL cells which are 
associated with multiple myeloma cells. An 
observation by Murphy et al. (2002) suggests 
that SLAMF7 is an active form of the two iso-
forms, which is targeted by Elotuzumab in the 
current treatment of multiple myeloma. We 
therefore suggest that the SLAMF7 isoform 
identified in our study might be a possible tar-
get by Elotuzumab for the treatment of CLL 
patients. Our study found over 50% positivity 
of SLAMF7 expression in the B-CLL cases 
studied.  
 
While extensive studies have been done with 
PMA, Bryostatins represent a newer discovery 
and provides the advantage of being anti-
promoters (Ueno et al., 2012). Differences in 
the extent and effect of the two PKC activators 
(PMA and Bryostatin) have been reported 
(Wender et al., 1988; Kedei et al., 2013a; 
Kedei et al., 2013b). In contrast to PMA, Bry-
ostatins do not have tumour promoting activity, 
but rather show anti-neoplastic features 
(Hennings et al., 1987; Nakagawa et al., 2009). 
In this study, 10 nM of bryostatin provided an 
effective concentration at which, activation of 
the B-CLL cells and SLAMF7 are optimal 
where 75% of all cases of B-CLL cells studied 
had increase in SLAMF7 receptors with bry-
ostatin modulation (Drexler et al., 1989). How-
ever, beyond this concentration, the SLAMF7 
receptors did not increase any further, suggest-
ing that increasing bryostatin beyond 10 nM 
might not increase the expression of receptors 
any more. The reason for this phenomenon 
cannot be explained and might require further 
nvestigation.   
 
The two identified isoforms of the SLAMF7 
(SLAMF7 and SLAMF7 A2) genes in this 
study (Fig 4), as have also been previously re-
ported by Murphy et al., (2002), were consid-
ered to be involved in the signal transduction 
pathway, with SLAMF7 noted as the active 
isoform. Not much information is known on the 
role of SLAMF7A2 in the immune cell. The  
 Ofosu et al. 70 
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RT-PCR study showed the presence of 
SLAMF7 and SLAMF7A2 in myeloma cells, 
(OMLS and MM1S), and also in the B-CLL 
cells (CB) (Fig 4). However, it is noted that the 
relative levels of expression of SLAMF7 are 
much higher in myeloma cells, compared to B-
CLL cells (Fig 4). Also in myeloma cells, the 
relative intensity of band 1 (SLAMF7) is higher 
than band 2 (SLAMF7A2), whereas in the B-
CLL cell, the two bands show equal intensity. 
These results were consistent with the findings 
of Murphy et al. (2002) and Ju et al. (2012) 




The study has demonstrated that SLAMF7 lev-
els of expression vary with different B-CLL 
cells, and the majority of these cells respond to 
PKC activators (PMA and Bryostatin) by in-
crease in proliferation, differentiation account-
ing for some changes in morphological charac-
teristics.  
 
Currently, Elotuzumab, a monoclonal antibody 
has been used to target high SLAMF7 express-
ing receptors in cells like myeloma cells. Our 
study has shown the high expression of 
SLAMF7 receptors on some B-CLL cells, im-
plying that without treatment with PKC activa-
tors, Elotuzumab could be used to treat some B
-CLL cells. This could provide a novel treat-
ment for CLL patients.  
 
Our study confirmed possible upregulation of 
the SLAMF7 receptors on B-CLL cells with 
PKC activators like PMA and Bryostatin. This 
could therefore lead to possible successful 
treatment of CLL patients who express low 
levels of SLAMF7 receptors. The study further 




The study could not measure the level of 
SLAMF7 expression levels after modulation. It  
is recommended that further studies be under-
taken to investigate the expression levels of  
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SLAMF7 gene after treatment with the PKC 
activators to determine the effect of this treat-
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